Syndax Pharmaceuticals Stock Price To Earnings To Growth
| SNDX Stock | USD 12.60 2.22 21.39% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Syndax Pharmaceuticals' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Syndax Pharmaceuticals Company Price To Earnings To Growth Analysis
Syndax Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Syndax Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Technical Analysis Now
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data |
| All Next | Launch Module |
Syndax Fundamentals
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | 344.28 M | ||||
| Shares Outstanding | 86.05 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 98.71 % | ||||
| Number Of Shares Shorted | 23.69 M | ||||
| Price To Earning | 126.11 X | ||||
| Price To Book | 3.99 X | ||||
| Price To Sales | 19.64 X | ||||
| Revenue | 23.68 M | ||||
| Gross Profit | (199.64 M) | ||||
| EBITDA | (313.82 M) | ||||
| Net Income | (318.76 M) | ||||
| Cash And Equivalents | 350.71 M | ||||
| Cash Per Share | 5.82 X | ||||
| Total Debt | 345.74 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 17.19 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | (274.9 M) | ||||
| Short Ratio | 11.64 X | ||||
| Earnings Per Share | (3.85) X | ||||
| Target Price | 32.67 | ||||
| Number Of Employees | 270 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 858.75 M | ||||
| Total Asset | 724.82 M | ||||
| Retained Earnings | (1.22 B) | ||||
| Working Capital | 499.51 M | ||||
| Current Asset | 79.72 M | ||||
| Current Liabilities | 13.32 M | ||||
| Net Asset | 724.82 M |
About Syndax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Syndax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.